Literature DB >> 11477564

Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer.

T Oguri1, T Isobe, K Fujitaka, N Ishikawa, N Kohno.   

Abstract

To investigate the roles played by the multidrug resistance-associated protein (MRP1) homologues MRP3 and MRP4 in resistance to platinum drugs, we examined steady-state levels of mRNA for both MRP3 and MRP4 in normal lung and lung cancer specimens as well as peripheral mononuclear cells (PMN) after platinum drug exposure. MRP3 and MRP4 gene expression levels were monitored in the PMN of 10 previously untreated lung cancer patients within 24 hr after carboplatin (CBDCA) administration. Expression levels for both genes were also examined in 80 autopsy samples (40 primary tumors and 40 corresponding normal lung tissues) from 40 patients with lung cancer. MRP3 and MRP4 gene expression levels were assessed by quantitative reverse transcription-polymerase chain reaction. MRP3 expression levels in the PMN rose rapidly within 24 hr after administration of CBDCA, whereas MRP4 expression levels remained the same. Furthermore, MRP3 expression levels in normal lung and tumor tissues from autopsy samples that had been exposed to platinum drugs while the patients were alive were significantly higher than those in unexposed tissues, but again MRP4 expression levels remained the same. These results suggest that platinum drugs and/or the physiological stress response to xenobiotics induce expression of the MRP3 gene. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477564     DOI: 10.1002/ijc.1369

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Organic cation transporter 6 directly confers resistance to anticancer platinum drugs.

Authors:  Tetsuya Oguri; Eiji Kunii; Satoshi Fukuda; Kazuki Sone; Takehiro Uemura; Osamu Takakuwa; Yoshihiro Kanemitsu; Hirotsugu Ohkubo; Masaya Takemura; Ken Maeno; Yutaka Ito; Akio Niimi
Journal:  Biomed Rep       Date:  2016-10-04

2.  Tissue platinum concentration and tumor response in non-small-cell lung cancer.

Authors:  Eric S Kim; J Jack Lee; Guangan He; Chi-Wan Chow; Junya Fujimoto; Neda Kalhor; Stephen G Swisher; Ignacio I Wistuba; David J Stewart; Zahid H Siddik
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

3.  Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance.

Authors:  Heng Jiang; Keli Chen; Jianming He; Feng Pan; Jianjun Li; Jianfang Chen; Wensheng Chen; Houjie Liang
Journal:  J Gastrointest Surg       Date:  2009-07-11       Impact factor: 3.452

Review 4.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

5.  The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.

Authors:  N Skrypek; B Duchêne; M Hebbar; E Leteurtre; I van Seuningen; N Jonckheere
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

Review 6.  ATP-binding cassette (ABC) transporters in normal and pathological lung.

Authors:  Margaretha van der Deen; Elisabeth G E de Vries; Wim Timens; Rik J Scheper; Hetty Timmer-Bosscha; Dirkje S Postma
Journal:  Respir Res       Date:  2005-06-20

7.  [Establishment of animal model of a human lung adenocarcinoma drug-resistant
cell line Anip973/NVB and investigation on mechanism of drug resistance].

Authors:  Meng Wang; Xuan Hong; Qinwen Sun; Ruilin Li; Zhaoyang Yang; Gongyan Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-03

8.  The genetic vulnerability to cisplatin ototoxicity: a systematic review.

Authors:  Evangelia Tserga; Tara Nandwani; Niklas K Edvall; Jan Bulla; Poulam Patel; Barbara Canlon; Christopher R Cederroth; David M Baguley
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

9.  Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.

Authors:  Tristan M Sissung; Arun Rajan; Gideon M Blumenthal; David J Liewehr; Seth M Steinberg; Arlene Berman; Giuseppe Giaccone; William D Figg
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

10.  Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

Authors:  K Pussegoda; C J Ross; H Visscher; M Yazdanpanah; B Brooks; S R Rassekh; Y F Zada; M-P Dubé; B C Carleton; M R Hayden
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.